The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.
Jason Edward Faris
No relevant relationships to disclose
Lawrence Scott Blaszkowsky
No relevant relationships to disclose
Thomas Adam Abrams
No relevant relationships to disclose
Peter C. Enzinger
No relevant relationships to disclose
Aram F. Hezel
Honoraria - Amgen; Bayer
Research Funding - Amgen
Brian M. Wolpin
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
Eunice Lee Kwak
No relevant relationships to disclose